OXA(17-33)
| Code | Size | Price |
|---|
| TAR-TP1973-1mg | 1mg | £297.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Potent and selective peptide orexin OX1 receptor agonist (EC50 values are 8.29 and 187 nM for OX1 and OX2 receptors respectively). Truncated form of orexin A.
CAS:
343268-91-7
Formula:
C79H125N23O22
Molecular Weight:
1749
Purity:
0.98
SMILES:
0
References
German et al (2013) Truncated orexin peptides: structure-activity relationship studies. Med.Chem.Lett. 4 1224 PMID:
Wang H N, Ji K, Zhang L N, et al. Inhibition of c-Fos expression attenuates IgE-mediated mast cell activation and allergic inflammation by counteracting an inhibitory AP1/Egr1/IL-4 axis[J]. 2021
Wang H N, Ji K, Zhang L N, et al. Inhibition of c-Fos expression attenuates IgE-mediated mast cell activation and allergic inflammation by counteracting an inhibitory AP1/Egr1/IL-4 axis. Journal of translational medicine. 2021 Jun 15;19(1):261. doi: 10.1186/s12967-021-02932-0.
Darker et al (2001) Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor. Bioorg.Med.Chem.Lett. 11 737 PMID: